Influenza Vaccines Market to Rise at 7.7% CAGR till 2026; Increasing Demand for Effective Flu Vaccines to Aid Market Expansion
The global influenza vaccines market size is slated to reach USD 7.34 billion by 2026, exhibiting a CAGR of 7.7% during the forecast period. Increasing prevalence of influenza worldwide will be the major driving force behind the growth of this market. According to the World Health Organization (WHO), around 3 to 5 million cases of influenza-based diseases are reported annually across the globe. This has spurred governments to take proactive measures to contain the spread of this deadly disease. Many governments carry out extensive vaccination drives before the flu season begins to immunize people from contracting any such infections, bolstering the seasonal influenza vaccines market demand.
According
to a new Fortune Business Insights™ report, titled “Influenza Vaccines Market Size, Share & Industry Analysis, By Type
(Inactivated, and Live Attenuated), By Valency (Quadrivalent and Trivalent), By
Age Group (Pediatric and Adults), By Distribution Channel (Hospital &
Retail Pharmacies, Government Suppliers and Others) and Geography Forecast,
2019-2026”, the value of this market stood at USD 4.05 billion in 2018. In
addition to market value, the report provides the following:
Request
Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/influenza-vaccine-market-101896
Top Players Profiled:
AstraZeneca
F. Hoffmann-La Roche Ltd
Sanofi
GlaxoSmithKline plc.
Sinovac Biotech Ltd
CSL Limited
Emergent BioSolutions Inc.
BioDiem
Presence of a Few Players to Make Competition Tight
Through its
influenza vaccines market report, Fortune Business Insights™ has brought out an
in-depth analysis of the competition in this market. The report states that the
competitive landscape will be dotted by a few key players who are increasing
their investment in enhancing their R&D capacities to widen their product
portfolio.
Key Industry Developments:
November 2019: Sanofi received clearance for its Fluzone® High-Dose
Quadrivalent from the US Food and Drug Administration (FDA). Containing an
additional Influenza B strain, the drug is designed and aimed at treating adults
at and over the age of 65.
January 2019: The European Commission green lit Seqirus’s
FLUCELVAX® TETRA for marketing in Europe. This is a cell-based quadrivalent
influenza vaccine, the first of its kind to be marketed in Europe, which is to
be used on people aged 9 years and above.
The global
influenza vaccines market size is slated to reach USD 7.34 billion by 2026,
exhibiting a CAGR of 7.7% during the forecast period. Increasing prevalence of
influenza worldwide will be the major driving force behind the growth of this market. According to the World
Health Organization (WHO), around 3 to 5 million cases of influenza-based
diseases are reported annually across the globe. This has spurred governments
to take proactive measures to contain the spread of this deadly disease. Many
governments carry out extensive vaccination drives before the flu season
begins to immunize people from contracting any such infections, bolstering the seasonal
influenza vaccines market demand.
About Us:
Fortune Business Insights™ offers
expert corporate analysis and accurate data, helping organizations of all sizes
make timely decisions. We tailor innovative solutions for our clients,
assisting them address challenges distinct to their businesses. Our goal is to
empower our clients with holistic market intelligence, giving a granular
overview of the market they are operating in. Our reports contain a unique mix
of tangible insights and qualitative analysis to help companies achieve
sustainable growth. Our team of experienced analysts and consultants use
industry-leading research tools and techniques to compile comprehensive market
studies, interspersed with relevant data.
Contact Us:
Fortune Business Insights Pvt.
Ltd.
9th Floor, Icon Tower, Baner -
Mahalunge Road,
Baner, Pune-411045,
Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email:
mailto:sales@fortunebusinessinsights.com
Comments
Post a Comment